Do we have any other variant perception playing out other than the special situation of Demerger. Considering 50%+ of its business is Caffeine and Xanthine derivatives, does it deserve a higher PE as it is more of a consumer proxy than a Pharma company?
| Subscribe To Our Free Newsletter |
